Pfizer’s Talzenna PARP breast cancer drug approved in USThe US drug regulator has approved Pfizer’s breast cancer medicine Talzenna (talazoparib) for patients with a certain mutation. Share XPfizer’s Talzenna PARP breast cancer drug approved in UShttps://pharmaphorum.com/news/pfizers-talzenna-parp-breast-cancer-drug-approved-in-us/
Roche and SQZ expand cell therapy deal to more than $1.3bnUS biotech SQZ Biotechnologies has expanded a collaboration with Roche to develop cancer therapies based on antigen presenting Share XRoche and SQZ expand cell therapy deal to more than $1.3bnhttps://pharmaphorum.com/news/roche-and-sqz-expand-cell-therapy-deal-to-more-than-1-3bn/
BMS Opdivo fails in small cell lung cancerBristol-Myers Squibb has said its Opdivo immunotherapy has failed to improve on standard of care in patients with Share XBMS Opdivo fails in small cell lung cancerhttps://pharmaphorum.com/news/bms-opdivo-fails-in-small-cell-lung-cancer/
BMS invests $12m in cancer immunotherapy tie-up with CompugenBristol-Myers Squibb has invested $12 million in Compugen, a biotech that is investigating a new approach that could Share XBMS invests $12m in cancer immunotherapy tie-up with Compugenhttps://pharmaphorum.com/news/bms-invests-12m-in-cancer-immunotherapy-tie-up-with-compugen/
Allogene astounds Wall Street with $324m IPO to fund cell therapy R&DGreat things were expected of Allogene Therapeutics’ IPO this week – the company is led by Arie Belldegrun Share XAllogene astounds Wall Street with $324m IPO to fund cell therapy R&Dhttps://pharmaphorum.com/news/allogene-astounds-wall-street-with-324m-ipo-to-fund-cell-therapy-rd/
Celltrion/Teva Rituxan biosimilar edges closer to US approvalIt looks increasingly likely that Roche’s cancer blockbuster Rituxan (rituximab) will face competition from a cheaper biosimilar in Share XCelltrion/Teva Rituxan biosimilar edges closer to US approvalhttps://pharmaphorum.com/news/celltrion-teva-rituxan-biosimilar-edges-closer-to-us-approval/
Pfizer’s leukaemia drug gets NHS funding in England and WalesPfizer’s Mylotarg has been approved by the English and Scottish NHS cost watchdogs as a restricted use treatment for Share XPfizer’s leukaemia drug gets NHS funding in England and Waleshttps://pharmaphorum.com/news/pfizers-leukaemia-drug-gets-nhs-funding-in-england-and-wales/
Celltrion’s Rituxan biosimilar gets glowing review ahead of key meetingReviewers from the FDA have given Celltrion’s biosimilar of Roche’s blood cancer blockbuster Rituxan a glowing report ahead Share XCelltrion’s Rituxan biosimilar gets glowing review ahead of key meetinghttps://pharmaphorum.com/news/celltrions-rituxan-biosimilar-gets-glowing-review-ahead-of-key-meeting/
NHS to reimburse Gilead’s CAR-T in adultsThe first CAR-T therapy aimed at adults with lymphoma is to be reimbursed in England after manufacturer Gilead Share XNHS to reimburse Gilead’s CAR-T in adultshttps://pharmaphorum.com/news/nhs-to-reimburse-gileads-car-t-in-adults/
Lilly’s breast cancer drug Verzenio approved in EUEli Lilly’s Verzenio breast cancer drug has been approved in Europe, as the pharma prepares to compete with Share XLilly’s breast cancer drug Verzenio approved in EUhttps://pharmaphorum.com/news/lillys-breast-cancer-drug-verzenio-approved-in-eu/
FDA says Clovis’ Rubraca could be prostate cancer breakthroughClovis Oncology’s Rubraca (rucaparib) has been designated as a Breakthrough Therapy by the FDA in prostate cancer, paving Share XFDA says Clovis’ Rubraca could be prostate cancer breakthroughhttps://pharmaphorum.com/news/fda-says-clovis-rubraca-could-be-prostate-cancer-breakthrough/
Gilead signs biotech deal arming T-cells to attack solid tumoursGilead’s Kite unit has signed a deal with the biotech HiFiBiO (High Fidelity Biology) to discover T-cell receptors Share XGilead signs biotech deal arming T-cells to attack solid tumourshttps://pharmaphorum.com/news/gilead-signs-biotech-deal-arming-t-cells-to-attack-solid-tumours/
Pfizer CEO Read to step down, COO Bourla takes the helmPfizer’s CEO Ian Read is to step down after eight years and will be replaced on 1st January Share XPfizer CEO Read to step down, COO Bourla takes the helmhttps://pharmaphorum.com/news/pfizer-ceo-read-to-step-down-coo-bourla-takes-the-helm/
Cancer immunotherapy pioneers awarded Nobel medicine prizeCancer immunotherapy pioneers James Allison and Tasuku Honjo have been awarded this year’s Nobel Prize in Physiology or Share XCancer immunotherapy pioneers awarded Nobel medicine prizehttps://pharmaphorum.com/news/cancer-immunotherapy-pioneers-awarded-nobel-medicine-prize/
US regulator backs Pfizer’s Vizimpro lung cancer drugThe US drug regulator has given Pfizer’s Vizimpro the green light in a group of lung cancer patients Share XUS regulator backs Pfizer’s Vizimpro lung cancer drughttps://pharmaphorum.com/news/us-regulator-backs-pfizers-vizimpro-lung-cancer-drug/
